A synthetic transaction can create regulatory-capital capacity by transferring credit risk. Whether that capacity becomes corporate lending, balance-sheet resilience or distributions is a separate decision.

Synthetic securitisation is often presented through a compelling chain of logic: transfer credit risk, release regulatory capital, lend more to the economy. The first link is structural. The second depends on prudential recognition. The third is a capital-allocation choice.

New ECB research makes that distinction unusually clear. Its conclusion is not that synthetic securitisation lacks value. The instrument can support risk management, concentration reduction and a more efficient capital structure. But the evidence does not support treating capital relief as proof of economically significant new lending.

For banks, investors and corporate borrowers, the useful question is therefore not simply how much capital a transaction appears to release. It is what risk has genuinely moved, what capacity has actually been created and where management intends to allocate it.

The loans stay; selected credit risk moves

In a traditional securitisation, a bank generally transfers loans to a special-purpose vehicle, which finances the acquisition by issuing securities. In a synthetic structure, the underlying loans remain on the originating bank’s balance sheet. What moves is a defined portion of their credit risk, normally through financial guarantees or credit derivatives.

The portfolio is divided into risk tranches. Investors providing protection absorb losses according to the transaction waterfall, while the bank pays a premium for that protection. If the arrangement achieves the required risk transfer and receives the applicable prudential recognition, the bank may reduce the regulatory capital attached to the protected portfolio.

That distinction is fundamental. Synthetic securitisation is primarily a risk-transfer and capital-management instrument. Unlike a true-sale structure, it does not inherently provide funding against a sale of assets. The originating bank still owns the loans, services the borrowers and remains exposed to risks not transferred by the contract.

A fast-growing market creates a larger allocation question

The ECB Blog reports that synthetic volumes have almost tripled since 2021. A related ECB working paper records that outstanding synthetic risk transfers backed by euro-area corporate loans increased from approximately €60 billion in 2018 to €300 billion at the end of 2024.

Banks clearly see strategic value in the instrument. In the ECB’s April 2026 bank lending survey, nearly half of 161 participating euro-area banks reported using traditional or synthetic securitisation. Synthetic significant risk transfer was the most frequently cited important form, and freeing capital to grant new loans was the primary motivation reported.

Motivation, capacity and outcome are nevertheless different facts. A bank can intend to support lending and still face weak credit demand, tighter underwriting, limited risk appetite or more attractive uses for the capacity. It may preserve capital buffers, absorb portfolio deterioration, fund growth elsewhere or distribute capital to shareholders.

The headline comparison is not the causal result

The ECB authors observe that banks issuing securitisations recorded average corporate-loan growth of around 5% between 2018 and 2025, compared with around 1% for non-issuers. That descriptive gap is striking, but it does not isolate securitisation from bank size, capital position or the wider economy.

After controlling for other factors and focusing on synthetics, the authors’ model finds that a 1% increase in issuance is associated with about a 0.02% increase in corporate-loan growth. They describe the effect as too small to have a substantial economic impact.

The same research finds a larger response in dividend payouts: approximately 0.07% for every 1% increase in synthetic issuance, around three times the estimated loan-growth response. These are modelled estimates from a defined dataset, not universal coefficients for every bank or transaction. But they challenge a convenient shortcut. Regulatory-capital relief expands the set of possible uses; it does not determine which use management will choose.

Four questions before calling it lending capacity

Boards assessing a synthetic transaction should separate four decisions.

1. Has meaningful risk actually transferred?

The legal form is not enough. Attachment points, tranche thickness, credit events, loss allocation, maturity and protection-provider obligations determine which losses move and which remain. Capital treatment depends on applicable rules and supervisory recognition; it should never be assumed from the word “synthetic”.

2. Is the protection durable through the portfolio’s risk horizon?

If protection matures before the underlying exposure, the bank may face rollover risk. If the protection provider cannot absorb losses, or the arrangement is insufficiently collateralised, the apparent transfer may become less effective precisely when the credit cycle weakens.

3. What will management do with the capacity?

“Support lending” is not an allocation plan. A credible plan identifies the portfolios, client segments, underwriting standards, return hurdles and time horizon against which deployment will be measured. It also distinguishes gross new originations from repayments, refinancings and balance-sheet rotation.

4. What resilience remains after deployment?

Using every unit of released capacity can increase leverage and reduce loss-absorbing headroom. The relevant measure is not maximum redeployment, but risk-adjusted deployment consistent with the bank’s capital plan, stress scenarios and concentration limits.

The borrower sees underwriting, not regulatory mechanics

For a corporate borrower, a bank’s capital relief is not a commitment to provide credit. Lending still depends on credit quality, sector appetite, collateral, covenants, pricing, maturity and portfolio limits. Even when securitisation supports volumes across the system, it may not ease standards for a particular company.

The ECB’s April survey captures this difference. Banks reported that securitisation supported lending volumes, especially to firms, while its contribution to easing credit standards was minimal. More capacity can therefore coexist with disciplined—or tighter—underwriting.

This is why corporate funding strategy should not rely on a general market narrative. Borrowers still need executable alternatives across bank debt, private credit, bonds, equity and transaction-specific structures, assessed on price, flexibility, certainty and strategic fit.

A better board scorecard

The success of a synthetic securitisation should be measured across the full chain, not at the capital-relief event alone:

risk transferred and retained;
prudential capital benefit actually recognised;
cost and durability of protection;
concentration and counterparty exposure;
allocation of released capacity;
incremental lending after repayments and substitution;
underwriting quality and borrower monitoring;
resilience under stress.

That scorecard avoids two opposite errors. One is to treat every synthetic transaction as financial engineering with no economic function. The other is to assume that every euro of capital released becomes a euro of productive new lending.

Synthetic securitisation can be a valuable part of bank capital management. Its economic contribution is not automatic. It begins with genuine risk transfer, continues with disciplined allocation and is ultimately proved by what the balance sheet can sustain—not by the transaction label.

Sources

This article is for general information only and does not constitute investment, legal, tax, accounting, regulatory, prudential, transaction or suitability advice. Capital treatment, risk transfer and transaction outcomes depend on the structure, counterparties, portfolio and applicable rules. Relevant qualified advisers and authorities should assess each case.